A5060237299- Neuroblastoma Research and Treatments
- Protein Degradation and Inhibitors
- Cancer, Hypoxia, and Metabolism
- Chromatin Remodeling and Cancer
- RNA Research and Splicing
- Cancer-related molecular mechanisms research
- RNA modifications and cancer
- Glioma Diagnosis and Treatment
- Adipose Tissue and Metabolism
- Cancer, Stress, Anesthesia, and Immune Response
- interferon and immune responses
- RNA and protein synthesis mechanisms
- Eicosanoids and Hypertension Pharmacology
- ATP Synthase and ATPases Research
Terry Fox Research Institute
2024-2025
University of British Columbia
2024-2025
Ghent University
2019-2023
Cancer Research Institute Ghent
2020-2022
Abstract The pediatric extra-cranial tumor neuroblastoma displays a low mutational burden while recurrent copy number alterations are present in most high-risk cases. Here, we identify SOX11 as dependency transcription factor adrenergic based on chromosome 2p focal gains and amplifications, specific expression the normal sympatho-adrenal lineage neuroblastoma, regulation by multiple (super-)enhancers strong high neuroblastomas. regulated direct targets include genes implicated epigenetic...
High-risk neuroblastoma, a pediatric tumor originating from the sympathetic nervous system, has low mutation load but highly recurrent somatic DNA copy number variants. Previously, segmental gains and/or amplifications allowed identification of drivers for neuroblastoma development. Using this approach, combined with gene dosage impact on expression and survival, we identified ribonucleotide reductase subunit M2 (RRM2) as candidate dependency factor further supported by growth inhibition...
ABSTRACT The pediatric extra-cranial tumor neuroblastoma (NB) is characterised by a low mutation burden while copy number alterations are present in most high-risk cases. We identified SOX11 as strong lineage dependency transcription factor adrenergic NB based on recurrent chromosome 2p focal gains and amplifications, its specific expression the normal sympatho-adrenal NBs regulation multiple cis-interacting (super-)enhancers. Adrenergic strongly dependent high levels for growth...
Summary Neuroblastoma is a pediatric tumor originating from the sympathetic nervous system responsible for 10-15 percent of all childhood cancer deaths. Half neuroblastoma patients present with high-risk disease at diagnosis. Despite intensive multi-modal therapies nearly 50 cases relapse and die their disease. In contrast to overall paucity mutations, invariably recurrent somatic segmental chromosome copy number variants. For several focal aberrations ( e.g. MYCN LIN28B amplification),...
Abstract Neuroblastoma (NB) is a pediatric cancer of the developing sympatho-adrenergic nervous system, responsible for 15% childhood deaths. Understanding fundamental underlying mechanisms NB key to early detection and appropriate treatment. High risk NBs are predominantly driven by DNA copy number alterations, including MYCN amplification, rare recurrent amplifications (affecting critical oncogenes LIN28B, ALK MDM2) large 2p 17q gains. Here we report on role focal gains SRY-related HMG-box...
Neuroblastoma (NB) is a pediatric cancer of the developing sympatho-adrenergic nervous system, responsible for 15% childhood deaths. Understanding fundamental underlying mechanisms NB key to early detection and appropriate treatment. High risk NBs are predominantly driven by DNA copy number alterations, including MYCN amplification, rare recurrent amplifications (affecting critical oncogenes LIN28B, ALK MDM2) large 2p 17q gains. Here we report on role focal gains SRY-related HMG-box...